Search Result

Results for "

HPK1 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FLT3 (1) IFNAR (1) Interleukin Related (3) MAP4K (59) PROTACs (3) Src (1)
By Research Areas:	Cancer (53) Infection (1) Inflammation/Immunology (22)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148847

HPK1-IN-32	MAP4K	Cancer
HPK1-IN-32 is a potent and selective *HPK1* inhibitor with an IC₅₀ of 65 nM. HPK1-IN-32 can be used for the research of HPK1 related disorders or diseases .

HY-160217

HPK1-IN-41	MAP4K	Cancer
HPK1-IN-41 (compound Z389) is an inhibitor of *HPK1* with an IC₅₀ value of 0.21 nM .

HY-156508

HPK1-IN-37	MAP4K	Cancer
HPK1-IN-37 (compound A85) is an inhibitor of HPK1 (IC₅₀=3.7 nM). HPK1-IN-37 can be used for research in HPK1 related disorders or diseases including cancers .

HY-168110

HPK1-IN-52	MAP4K	Cancer
HPK1-IN-52 is a potent and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 10.4 nM. HPK1-IN-52 exhibits anti-tumor activities .

HY-149520

HPK1-IN-39	MAP4K	Cancer
HPK1-IN-39 (Compound 10n) is a selective *HPK1* Inhibitor (IC₅₀: 29 nM). HPK1-IN-39 inhibits the phosphorylation of SLP76. HPK1-IN-39 can be used for research of cancer immunotherapy .

HY-144073

HPK1-IN-21	MAP4K	Cancer
HPK1-IN-21 is a potent inhibitor of *HPK1* kinase inhibitor (Ki=0.8 nM). HPK1-IN-21 also has orally active .

HY-144091

HPK1-IN-24	MAP4K	Cancer
HPK1-IN-24 (example 51) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a K_i of 100 nM. HPK1-IN-24 has the potential for cancer research .

HY-163496

HPK1-IN-45	MAP4K	Cancer
HPK1-IN-45 (Compound 3) is a *HPK1* inhibitor, with an IC₅₀ of 0.3 nM. HPK1-IN-45 inhibits SLP-76 phosphorylation (IC₅₀ = 57.52 nM) and IL-2 release (IC₅₀ = 38 nM). HPK1-IN-45 can be used for the research of cancer .

HY-157149

DS21150768	MAP4K	Cancer
DS21150768 is a potent, orally active *HPK1* inhibitor. DS21150768 shows potent activity to enhance T-cell function. DS21150768 has anticancer effects .

HY-156509

HPK1-IN-38	MAP4K	Others
HPK1-IN-38 (compound 15) is a *MAP4K1/HPK1* inhibitor，can be used for HPK1 related disorders research .

HY-132926

HPK1-IN-8	MAP4K	Cancer
HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length *HPK1*.

HY-144092

HPK1-IN-25	MAP4K	Cancer
HPK1-IN-25 (example 94) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor with a enzymatic activity IC₅₀ of 129 nM. HPK1-IN-25 has the potential for cancer research .

HY-149206

HPK1-IN-33	MAP4K	Cancer
HPK1-IN-33 (compound 21) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a K_i value of 1.7 nM. HPK1-IN-33 inhibits the produce of IL-2 with EC₅₀s of 286, >10000 nM in Jurkat WT and Jurkat HPK1 KO cells, respectively .

HY-163372

PROTAC HPK1 Degrader-1	MAP4K PROTACs	Cancer
PROTAC HPK1 Degrader-1 (Compound B1) is a potent *HPK1* degrader with DC₅₀ value of 1.8 nM. PROTAC HPK1 Degrader-1 inhibits phosphorylation of the SLP76 protein with IC₅₀ value of 496.1 nM. PROTAC HPK1 Degrader-1 is a bona fide *HPK1-PROTAC* degrader, which provided a potential tool for further HPK1 investigation in TCR signaling .

HY-144093

HPK1-IN-26	MAP4K	Infection
HPK1-IN-26 is a *HPK1* and GLK inhibitor extracted from patent WO2021254118A1 compound 1. HPK1-IN-26 can be used for the research of animal pathogen infection .

HY-145109

HPK1-IN-20	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-20 (Compound 106) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor .

HY-173006

AZ3246	MAP4K Interleukin Related	Cancer
AZ3246 is an orally active and selective inhibitor of *HPK1* with an IC₅₀ < 3 nM. AZ3246 induces IL-2 secretion in T cells with an EC₅₀ of 90 nM. AZ3246 is a low-volume, low-clearance antitumor compound .

HY-160218

HPK1-IN-42	MAP4K	Cancer
HPK1-IN-42 (compound 185) ia a *HPK1* inhibitor with the IC₅₀ 50 of 0.24 nM .

HY-153448

HPK1-IN-36	MAP4K	Cancer
HPK1-IN-36 (compound 2) is a potent *HPK1* inhibitor with an IC₅₀ value of 0.5 nM .

HY-168119

HPK1-IN-53	MAP4K	Cancer
HPK1-IN-53 (compund 3a) is the potent *HPK1* inhibitor (IC₅₀=48 nM) .

HY-143869

HPK1-IN-28	MAP4K	Cancer
HPK1-IN-28 is a potent inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1*-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) .

HY-143870

HPK1-IN-29	MAP4K	Cancer
HPK1-IN-29 is a potent inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1*-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) .

HY-149232

HPK1-IN-35	MAP4K	Cancer
HPK1-IN-35 is a potent and selective *HPK1* inhibitor with an IC₅₀ value of 3.5 nM. HPK1-IN-35 decreases the expression of p-SLP76 and promotes IL-2 secretion .

HY-172107

HPK1-IN-56	MAP4K Interleukin Related	Inflammation/Immunology Cancer
HPK1-IN-56 (Compound A29) is a *HPK1* inhibitor (IC₅₀: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC₅₀: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody .

HY-145039

HPK1-IN-13	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-13 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-13 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 64) .

HY-145038

HPK1-IN-12	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-12 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-12 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 85) .

HY-145040

HPK1-IN-14	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-14 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-14 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 79) .

HY-145035

HPK1-IN-9	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-9 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) .

HY-145037

HPK1-IN-11	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-11 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-11 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 2) .

HY-145036

HPK1-IN-10	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-10 is potent inhibitor of *HPK1. HPK1* is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) .

HY-161335

HPK1-IN-43	MAP4K Interleukin Related IFNAR	Cancer
HPK1-IN-43 (compound 9f) is a *HPK1* kinase inhibitor with the IC₅₀ value of 0.32 nM. HPK1-IN-43 inhibits the phosphorylation of the downstream protein SLP-76 and enhances the secretion of interleukin-2 (IL-2) and interferon-γ (IFN-γ). HPK1-IN-43 can be used in cancer research .

HY-145107

HPK1-IN-19	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-19 (Compound I-47) is a hematopoietic progenitor kinase 1 (HPK1) inhibitor .

HY-163717

HPK1-IN-48	MAP4K	Cancer
HPK1-IN-48 (compound 14g) is a potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor with a IC₅₀ of 0.15 nM. HPK1-IN-48 significantly suppresses the phosphorylation of SLP76 with a IC₅₀ of 27.92 nM .

HY-170365

HPK1-IN-55	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-55 (compound 19) is a selective and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ of <0.51 nM. HPK1-IN-55 shows excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK). HPK1-IN-55 has anticancer effects .

HY-152257

HPK1-IN-31	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-31 (compound 5i) is an orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunoresearch .

HY-159905

HPK1-IN-54	MAP4K	Inflammation/Immunology
HPK1-IN-54 is a potent *HPK1* (Hematopoietic Progenitor Kinase 1) inhibitor that enhances T cell activation and proliferation by inhibiting *HPK1* activity, thereby exhibiting antitumor effects. Its IC₅₀ value against *HPK1* is 2.67 nM, with excellent selectivity over the MAP4K family (>100-fold) and other selected kinases (>300-fold). HPK1-IN-54 displayed moderate in vivo clearance and reasonable oral exposure in mice and rats. Additionally, HPK1-IN-54 demonstrated strong antitumor efficacy in a CT26 murine colon cancer model and synergistic effects when combined with anti-PD-1 (HY-P9902A). HPK1-IN-54 shows promise for research in the field of immunotherapy .

HY-163495

HPK1-IN-44	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-44 (Compound 1) is an inhibitor of *HPK1* (IC₅₀=0.1 nM (40 μM ATP)) .

HY-161917

HPK1-IN-49	MAP4K	Inflammation/Immunology
HPK1-IN-49 (Compound I-4) is an inhibitor for hematopoietic progenitor kinase 1 (HPK1) with an IC₅₀ >100 nM .

HY-138569

HPK1-IN-4	MAP4K	Cancer
HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC₅₀ of 0.061 nM) as preclinical immunoresearch tool compound .

HY-143868

HPK1-IN-27	MAP4K	Cancer
HPK1-IN-27 is a potent inhibitor of *HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1*-IN-27 has the potential for the research of cancer diseases (extracted from patent WO2019016071A1, compound 38) .

HY-143871

HPK1-IN-30	MAP4K	Cancer
HPK1-IN-30 is a potent inhibitor of *HPK1. MAP4K1 is also known as hematopoietic progenitor kinase 1 (HPK1). MAP4K1 is a serine/threonine kinase and member of the germinal center kinase family. HPK1*-IN-30 has the potential for the research of cancer diseases (extracted from patent WO2021175271A1, compound 3) .

HY-153362

HPK1-IN-34	MAP4K	Cancer
HPK1-IN-34 (Compound 143) is a Hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC₅₀ of <100 nM . HPK1-IN-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-135892

GNE-1858 2 Publications Verification	MAP4K	Inflammation/Immunology
GNE-1858 is a potent and ATP-competitive hematopoietic progenitor kinase-1 (HPK1) inhibitor, with IC₅₀s of 1.9 nM, 1.9 nM, and 4.5 nM for wild-type and the active mimetic mutants HPK1-TSEE and HPK1-SA, respectively .

HY-149773S

HPK1-IN-40-d2	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-40 (compound 49) is a potent and selective *HPK1* inhibitor with an IC₅₀ of 0.9 nM. HPK1-IN-40 reinvigorates T-cell receptor (TCR) signaling, promoting T-cell function and cytokine production in T cells while having anti-cancer activity .

HY-145041

HPK1-IN-15	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-15 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-15 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2018049200A1, compound 50) .

HY-145042

HPK1-IN-16	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-16 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-16 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2019051199A1, compound 39) .

HY-145044

HPK1-IN-17	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-17 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-17 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2019238067A1, compound 73) .

HY-145045

HPK1-IN-18	MAP4K	Inflammation/Immunology Cancer
HPK1-IN-18 is a potent and selective inhibitor of *HPK1. Hematopoietic progenitor kinase 1 (HPKl) originally cloned from hematopoietic progenitor cells is a member of MAP kinase kinase kinase kinases (MAP4Ks) family. HPK1-IN-18 is useful in researching, preventing or ameliorating diseases or disorders associated with HPK1* activity such as cancer (extracted from patent WO2019238067A1, compound 1) .

HY-138742

HPK1-IN-7	MAP4K	Cancer
HPK1-IN-7 is a potent, orally active *HPK1* (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC₅₀=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1 .

HY-138568

HPK1-IN-3	MAP4K	Inflammation/Immunology
HPK1-IN-3 is a potent and selective ATP-competitive *hematopoietic progenitor kinase 1 (HPK1; MAP4K1)* inhibitor with an IC₅₀ of 0.25 nM. HPK1-IN-3 has IL-2 cellular potency with an EC₅₀ of 108 nM in human peripheral blood mononuclear cells (PBMCs) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: